Literature DB >> 26785389

The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment.

Stefano Ballestri1, Fabio Nascimbeni2, Dante Romagnoli2,3, Amedeo Lonardo2,3.   

Abstract

AIM: The diagnosis of non-alcoholic steatohepatitis (NASH) is based on the individual histological features: steatosis, lobular inflammation and ballooning. Non-alcoholic fatty liver disease (NAFLD) activity score (NAS ≥ 5) is used in clinical trials. Fibrosis dictates long-term NAFLD prognosis. Recently, more-than-mild portal inflammation has raised interest as a marker of NAFLD severity. We assessed the independent predictors of: (I) individual histological lesions of NASH; (II) diagnosis of NASH; (III) significant (stage ≥2) and advanced (stage ≥3) fibrosis; and (IV) more-than-mild portal inflammation.
METHODS: Data from 118 consecutive biopsy-proven NAFLD patients observed at our institution were retrospectively analyzed.
RESULTS: At stepwise multivariate logistic regression analyses, independent predictors were as follows. For the individual histological features of NASH: insulin resistance (IR), assessed with Homeostasis Model Assessment-IR (HOMA-IR), serum uric acid (SUA) and serum total cholesterol (TCH) for moderate-to-severe steatosis; waist circumference (waist), HOMA-IR and TCH for lobular inflammation; waist, HOMA-IR, metabolic syndrome (MS), serum alanine aminotransferase (ALT), SUA and TCH for ballooning. For NASH diagnosis: waist, HOMA-IR, MS, ALT, SUA and TCH (Brunt et al.'s classification); ALT, SUA and TCH for NAS ≥ 5. For significant and advanced fibrosis, respectively: waist, MS and ALT; age, platelets, HOMA-IR, diabetes and TCH. For more-than-mild portal inflammation: serum aspartate aminotransferase (AST), serum iron, NAS ≥ 5 and significant liver fibrosis.
CONCLUSION: HOMA-IR, SUA, MS, ALT and TCH are independent predictors of NASH and its individual histological lesions, notably including fibrosis. Based on our findings, these factors should be considered major pathogenic drivers of NASH and, by inference, potential targets for treatment.
© 2016 The Japan Society of Hepatology.

Entities:  

Keywords:  HOMA-IR; NAFLD; fibrosis; inflammatory grading; iron; steatosis

Year:  2016        PMID: 26785389     DOI: 10.1111/hepr.12656

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  51 in total

1.  Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.

Authors:  Yuya Seko; Yoshio Sumida; Kazuyo Sasaki; Yoshito Itoh; Hiroaki Iijima; Toshio Hashimoto; Shinichi Ishii; Nobuya Inagaki
Journal:  J Gastroenterol       Date:  2017-07-01       Impact factor: 7.527

Review 2.  Drug-induced steatohepatitis.

Authors:  Ajit Dash; Robert A Figler; Arun J Sanyal; Brian R Wamhoff
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-10-27       Impact factor: 4.481

Review 3.  The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View.

Authors:  Christina C Lindenmeyer; Arthur J McCullough
Journal:  Clin Liver Dis       Date:  2018-02       Impact factor: 6.126

Review 4.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

5.  Type 2 Diabetes Mellitus and Simple Glucose Metabolism Parameters may Reliably Predict Nonalcoholic Fatty Liver Disease Features.

Authors:  Everton Cazzo; Laísa Simakawa Jimenez; Martinho Antonio Gestic; Murillo Pimentel Utrini; Fábio Henrique Mendonça Chaim; Felipe David Mendonça Chaim; José Carlos Pareja; Elinton Adami Chaim
Journal:  Obes Surg       Date:  2018-01       Impact factor: 4.129

6.  Active p38α causes macrovesicular fatty liver in mice.

Authors:  Ilona Darlyuk-Saadon; Chen Bai; Chew Kiat Matthew Heng; Nechama Gilad; Wei-Ping Yu; Pei Yen Lim; Amaury Cazenave-Gassiot; Yongliang Zhang; W S Fred Wong; David Engelberg
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

7.  Correlation Between Anthropometric Measurements and Non-alcoholic Fatty Liver Disease in Individuals With Obesity Undergoing Bariatric Surgery: Cross-Sectional Study.

Authors:  Silênio Souza Reis; Guilherme Hoverter Callejas; Rodolfo Araújo Marques; Martinho A Gestic; Murillo P Utrini; Felipe D M Chaim; Almino C Ramos; Elinton A Chaim; Everton Cazzo
Journal:  Obes Surg       Date:  2021-05-12       Impact factor: 4.129

Review 8.  Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions.

Authors:  Tomas Hrncir; Lucia Hrncirova; Miloslav Kverka; Robert Hromadka; Vladimira Machova; Eva Trckova; Klara Kostovcikova; Pavlina Kralickova; Jan Krejsek; Helena Tlaskalova-Hogenova
Journal:  Microorganisms       Date:  2021-04-29

9.  Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease.

Authors:  Haluk Tarik Kani; Coskun Ozer Demirtas; Caglayan Keklikkiran; Ilkay Ergenc; Shahin Mehdiyev; Esra Akdeniz; Yusuf Yilmaz
Journal:  Turk J Gastroenterol       Date:  2021-08       Impact factor: 1.852

Review 10.  Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.

Authors:  Stefano Ballestri; Fabio Nascimbeni; Dante Romagnoli; Enrica Baldelli; Giovanni Targher; Amedeo Lonardo
Journal:  Int J Mol Sci       Date:  2016-03-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.